Mucolytic effect of the oral, injectable and inhaled forms of N-acetyl cysteine drug in Chronic Obstructive pulmonary Disease and concurrent pneumonia

Evaluation the mucolytic effect of the oral, injectable and inhaled forms of N-acetyl cysteine (NAC) in hospitalized patients with Chronic Obstructive pulmonary Disease (COPD) and concurrent pneumonia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241218064092N1

Enrollment

Registered

2025-01-04

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Chronic Obstructive Pulmonary Disease (COPD). Condition 2: Pneumonia. Chronic obstructive pulmonary disease with (acute) exacerbation Unspecified infectious disease

Interventions

Intervention 1: Intervention group 1 : Oral form of N_AcetylCysteine 600 mg every 6 hours. Intervention 2: Intervention group 2 :" Intravenous form of N_AcetylCysteine 100 mg every 6 hours. Interventi

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: COPD and pneumonia at the same time Availability of medical records Hospitalization in the lung and general departments with chief complaint related to COPD with pneumonia No treatment with NAC before the study

Exclusion criteria

Exclusion criteria: Breastfeeding Pregnancy Significant defect in the information in medical record Use of the other mucolytic and expectorant NAC drug sensitivity Cystic Fibrosis and other lung diseases Underlying diseases with muscle weakness such as Myasthenia Gravis, Amyotrophic Lateral Sclerosis and Cerebral Vasculat Accident

Design outcomes

Primary

Measure	Time frame
Ability of excretion sputum. Timepoint: Before intervention and third day and at the end of hospitalization. Method of measurement: Visual Analogue Scale less than 4 and reducing score of Chronic Obstructive Pulmonary Disease Assessment Test.;The number of cough. Timepoint: Before intervention and third day and at the end of hospitalization. Method of measurement: Visual Analogue Scale less than 4 and reducing score of Chronic Obstructive Pulmonary Disease Assessment Test.;Volume of sputum. Timepoint: Before intervention and third day and at the end of hospitalization. Method of measurement: Visual Analogue Scale less than 4 and reducing score of Chronic Obstructive Pulmonary Disease Assessment Test.;C_Reactive Protein. Timepoint: Before intervention and third day and at the end of hospitalization. Method of measurement: C_Reactive Protein test.	—

Measure

Time frame

Ability of excretion sputum. Timepoint: Before intervention and third day and at the end of hospitalization. Method of measurement: Visual Analogue Scale less than 4 and reducing score of Chronic Obstructive Pulmonary Disease Assessment Test.;The number of cough. Timepoint: Before intervention and third day and at the end of hospitalization. Method of measurement: Visual Analogue Scale less than 4 and reducing score of Chronic Obstructive Pulmonary Disease Assessment Test.;Volume of sputum. Timepoint: Before intervention and third day and at the end of hospitalization. Method of measurement: Visual Analogue Scale less than 4 and reducing score of Chronic Obstructive Pulmonary Disease Assessment Test.;C_Reactive Protein. Timepoint: Before intervention and third day and at the end of hospitalization. Method of measurement: C_Reactive Protein test.

—

Secondary

Measure	Time frame
Cost for more appropriate treatment. Timepoint: At the end of hospitalization. Method of measurement: Comparing effect of N_Acetyl Cysteine in oral,injectable and inhaled forms with each other.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnaz Torbat Isfahani

Zanjan University of Medical Sciences

behnaz.torbat@gmail.com+98 21 8860 4154

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026